The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease

Calcified Tissue International

Volumn 81, Issue 5, 2007, Pages 341-351

  Brown, J E ^a,h   McCloskey, E V ^a   Dewar, J A ^b   Body, J J ^c   Cameron, D A ^d   Harnett, A N ^e   Ruutu, M ^f   Purohit, O P ^a   Tahtela R ^g   Coleman, R E ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NINEWELLS HOSPITAL   (United Kingdom)

^c JULES BORDET INSTITUTE   (Belgium)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

^e NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^f Maria Hospital   (Finland)

^g Mehilainen Oy   (Finland)

^h ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Bone alkaline phosphatase; Clodronate; Metastatic bone disease; Serum C terminal cross linking telopeptide of type I collagen; Urinary N terminal cross linking telopeptide of type I collagen

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CLODRONIC ACID; COLLAGEN TYPE 1; PLACEBO;

ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CALCIUM URINE LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOCALCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OSTEOLYSIS; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; URINE RETENTION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CALCIUM; CLODRONIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLACEBOS; PREDICTIVE VALUE OF TESTS; PROCOLLAGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 35948993387     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-007-9061-x     Document Type: Article

References (34)

1. Woitge HW, Pecherstorfer M, Li Y, Keck AV, Horn E, Ziegler R, Seibel MJ (1999) Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 14:792-801
2. Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC, Lipton A (2002) Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20:850-856
3. Vinholes JJ, Purohit OP, Abbey ME, Eastell R, Coleman RE (1997) Relationship between biochemical and symptomatic response in a double blind trial of pamidronate for metastatic bone disease. Ann Oncol 8:1243-1250
4. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925-4935
5. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59-69
6. Lipton A, Costa L, Ali SM, Demers LM (2001) Bone markers in the management of metastatic bone disease. Cancer Treat Rev 27:181-185
7. Brown JE, Thomson C, Ellis S, Gutcher SA, Purohit O-P, Coleman RE (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89:2031-2037
8. Elomaa I, Blomqvist C, Grohn P, Porkka L, Kairento AL, Selander K, Lamberg-Allardt C, Holmstrom T (1983) Long-term controlled trial with diphosphonate in patient with osteolytic bone metastases. Lancet 1:146-148
9. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S (1993) Double blind trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65
10. Taube T, Kylmala T, Lamberg-Allardt C, Tammela TL, Elomaa I (1994) The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind, randomized, placebo-controlled study. Eur J Cancer 30A:751-758
11. McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT (2001) Long term follow up of a prospective, double blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 113:1035-1043
12. Diel IJ, Marschner M, Kindler O (1998) Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases. Proc ASCO 18:128a
13. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Mannisto E, Suovuori A, Atula S, Nevalainen J, Pylkkanen L (2002) Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20:3219-3224
14. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J (2006) Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res 8:R13
15. O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA (1995) Double-blind, placebo-controlled, dose-response trial of clodronate in patients with bone metastases. J Clin Oncol 13:929-934
16. Vinholes J, Coleman R, Eastell R (1996) Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev 22:289-331
17. Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE (1996) Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer 73:1089-1095
18. Oken MM, Creech RH, Tormey DC (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655
19. Saha H, Castren-Kortekangas P, Ojanen S, Juhakoski A, Tuominen J, Tokola O, Pasternack A (1994) Pharmacokinetics of clodronate in renal failure. J Bone Miner Res 9:953-958
20. Castren-Kortekangas P, Loyttyniemi E, Liukko-Sipi S, Juhakoski A, Smal J, Laitinen K (1997) Pooling of clodronate urinary excretion data: a new pharmacokinetic method to study drugs with highly variable gastrointestinal absorption. J Bone Miner Res 12:66-71
21. Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, Greenspan SL (1998) Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif Tissue Int 63:363-368
22. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B; Zoledronic Acid Prostate Cancer Study Group (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468
23. Jagdev SP, Purohit P, Heatley S, Herling C, Coleman RE (2001) Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 12:1433-1438
24. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377-387
25. Body JJ, Dumon JC, Blocklet D, Darte C (1997) The bone isoenzyme of alkaline phosphatase in hypercalcaemic patients. Eur J Cancer 33:1578-1582
26. Fromigué O, Body JJ (2002) Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 25:539-546
27. Li X, Liu P, Liu W, Maye P, Zhang J, Zhang Y, Hurley M, Guo C, Boskey A, Sun L, Harris SE, Rowe DW, Ke HZ, Wu D (2005) Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet 37:945-952
28. Robertson AG, Reed NS, Ralston SH (1995) Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 13:2427-2430
29. Ernst DS, Brasher P, Hagen N, Paterson AH, MacDonald RN, Bruera E (1997) A randomized controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage. 13:319-326
30. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ (1998) Long term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group 1998. J Clin Oncol 16:2038-2044
31. Diel IJ, Body JJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergstrom B (2004) Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40:1704-1712
32. Kohno N, Aogi K, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314-3321
33. Durie BG, Katz M, Crowley J (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99-102
34. Woo SB, Hellstein JW, Kalmar JR (2006) Systematic review. Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753-761